| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Tvardi Therapeutics, Inc. (TVRD) has 5 insiders with recent SEC Form 4 filings, including 5 buys and 8 sells. TVRD is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 47.5K | $198.6K | - | |
| Other | 17.5K | $73.2K | - | |
| CFO | 17.5K | $73.2K | - | |
| Other | 4.0K | $16.7K | - | |
| 10% | 0 | - | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jan 24, 2018 | Menzaghi Frederique Ph.d.85 | Sr Vp-research &Development | Sell | 15,000 | $15.00 | $225,000.00 | -10.9% | |
| Nov 1, 2017 | Chalmers Derek T | President &CEO | Sale+OE | 16,000 | $12.66 | $202,560.00 | -1.5% | |
| Aug 4, 2017 | Menzaghi Frederique Ph.d.85 | Vp-research &Development | Sell | 3,000 | $15.00 | $45,000.00 | -2.5% | |
| Jul 14, 2017 | Chalmers Derek T | President &CEO | Sale+OE | 25,000 | $15.05 | $376,250.00 | -2.3% | |
| Jul 14, 2017 | Menzaghi Frederique Ph.d.85 | Vp-research &Development | Sell | 3,000 | $15.00 | $45,000.00 | -2.4% | |
| Jun 29, 2017 | Slagel Dean | Director | Sell | 250,000 | $25.87 | $6,468,563.74 | -10.4% | |
| Mar 31, 2017 | Rho Ventures VI LP | 10% Owner | Buy | 500,000 | $18.19 | $9,095,700.00 | +16.3% | |
| Apr 20, 2016 | Menzaghi Frederique Ph.d.85 | Vp-research &Development | Sell | 6,000 | $9.00 | $54,000.00 | -4.7% | |
| Mar 17, 2016 | Rho Ventures VI LP | 10% Owner | Buy | 400,000 | $4.87 | $1,949,202.91 | +7.3% | |
| Mar 17, 2016 | Vogelbaum Martin | Director | Buy | 400,000 | $4.87 | $1,949,202.91 | +7.3% |